Quince Therapeutics

Quince Therapeutics is a company listed under the stock ticker CRTX (US).

View the org chart displaying its 18 main executives

Most searched biographies at Quince Therapeutics

• Dirk Thye, Chief Executive Officer
• Margaret McLoughlin, Director
• David Lamond, Chairman of the Board

Popular executive movements at Quince Therapeutics

• Rajiv Patni has joined the company as Director  (posted on February 16 2024).
• Charles Ryan has joined the company as President  (posted on September 7 2023).

Create your alert
to follow the executive moves at Quince Therapeutics.

Quince Therapeutics has 1,819 competitors including Siemens Healthineers (Germany), IQVIA (United States (USA)) and Saint Francis Health System (United States (USA)).

Popular M&A news in Healthcare

• Midi Health has just announced a $60 Million fundraising (posted on April 29 2024).
• Xaira Therapeutics becomes a unicorn with its fundraising of $1,000 Million. (posted on April 25 2024).
• Two Chairs has just announced a $72 Million fundraising (posted on April 18 2024).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Bryan Roberts - Director at Included Health
• Sima Sistani - Chief Executive Officer and Director at WW International

Learn more about the Healthcare industry >

Press releases by Quince Therapeutics

• Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors | Cortexyme
• Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population | Cortexyme
• Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders | Cortexyme
• Cortexyme to Present New GAIN Trial Data at AD/PD 2022 | Cortexyme
• Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021 | Cortexyme
• Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588 | Cortexyme
• Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th | Cortexyme
• Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit | Cortexyme
• Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit | Cortexyme
• Cortexyme Provides Business Update and Reports Second Quarter 2021 Results | Cortexyme
• View more press releases Close

Social media about Quince Therapeutics

• Quince Therapeutics on Wikipedia, Google News & Yahoo Finance
• Quince Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Dirk Thye

Call Quince Therapeutics at +1 650...

View the org chart

Register to receive your alert

Report an error